This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OPKO To Hold Conference Call To Discuss Six Month Data From Phase 2 HGH-CTP Trial

OPKO Health, Inc. (NYSE: OPK), a multinational biopharmaceutical and diagnostics company that is developing a novel long-acting human growth hormone product (hGH-CTP) for the treatment of growth hormone deficiency (GHD), today announced it will hold a conference call and webcast on Tuesday, June 24, 2014 at 8:30 a.m. EDT (7:30 a.m. CDT).

During the call, OPKO Biologics management will discuss data from the company's advanced phase 2 trial of hGH-CTP in growth hormone deficient pediatric subjects. The pharmacokinetic and pharmacodynamics portion of the results will also be presented at a poster presentation on the prior Monday afternoon from 2:00 p.m. to 4:00 p.m. EDT (1:00 p.m. to 3:00 p.m. CDT) during the International Congress of Endocrinology and Endocrine Society's Annual Meeting and Expo at the McCormick Place West in Chicago, IL. The poster is titled “Pharmacokinetics and Pharmacodynamics Profile of Once-Weekly, CTP-Modified Human Growth Hormone (MOD-4023): Phase 2 Dose Finding Study in Children with GH Deficiency”. An additional poster titled “Production and Characterization of MOD-4023, a LONG Acting Growth Hormone and Supporting Clinical and Commercial Drug Product Supply” will be presented in parallel.

The data to be discussed during the call will include six month height velocity and safety data from the company’s phase 2 trial, which is a one year dose finding study administering hGH-CTP to growth hormone deficient children once a week using daily hGH as a comparator arm. These data affirmed that a single weekly injection of hGH-CTP has the potential to replace seven consecutive daily injections of currently marketed hGH, further validating the optimal dose and dosing regimen for the upcoming phase 3 trial in pediatric patients. In addition, hGH-CTP demonstrated a very good safety and tolerability profile in this ongoing study, with no unexpected adverse events.

Conference Call and Webcast

OPKO will hold a conference call on Tuesday, June 24, 2014 at 8:30 a.m. EDT (7:30 a.m. CDT). The dial-in numbers are 1-877-407-0789 for domestic callers and 1-201-689-8562 for international callers. A webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.opko.com.

After the webcast, the call will remain available on the OPKO website, www.opko.com, for 30 days.

About hGH-CTP

In June 2013, OPKO initiated a pivotal phase 3 clinical trial in adults of its proprietary long-acting version of hGH-CTP. hGH-CTP has been awarded orphan drug designation in the U.S. and Europe for both adults and children with growth hormone deficiency.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,262.71 -23.03 -0.13%
S&P 500 2,129.25 -1.57 -0.07%
NASDAQ 5,096.9430 +6.1490 0.12%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs